HAMBURG, Germany, May 18, 2011 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) and Roche (SWX:RO) (SWX:ROG) (OTCQX:RHHBY) today decided to voluntarily terminate the first proof-of-concept study ...
Company Today Also Provided Updates on R&D Portfolio and Strategy at Investor Event Crinecerfont New Drug Application Submission Planned in 2024 NBI-'770, an Oral NMDA NR2B Negative Allosteric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback